Takeda Pharmaceutical Company L (TAK) Financials
TAK Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 100.9 billion | 53.0 billion |
| 2023-09-30 | 99.6 billion | 52.2 billion |
| 2023-06-30 | 102.3 billion | 54.5 billion |
| 2023-03-31 | 105.1 billion | 57.2 billion |
TAK Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | 491.6 million | 132.6 million |
| 2023-09-30 | 862.7 million | 124.1 million |
| 2023-06-30 | -1.2 billion | 106.8 million |
| 2023-03-31 | -1.1 billion | 111.8 million |
TAK Net Income
| Date | Net Income |
|---|---|
| 2023-12-31 | 749.9 million |
| 2023-09-30 | -321.1 million |
| 2023-06-30 | 618.5 million |
| 2023-03-31 | 234.4 million |
TAK Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 2.3 billion | - | - |
| 2023-09-30 | 2.2 billion | 29.5 billion | - |
| 2023-06-30 | 2.6 billion | 30.0 billion | - |
| 2023-03-31 | 4.2 billion | 30.4 billion | - |
TAK Shares Outstanding
TAK Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 546.9 million | 1.3 billion | 1.9 billion | - |
| 2023-09-30 | 468.9 million | 1.2 billion | 1.7 billion | - |
| 2023-06-30 | 1.9 billion | 1.1 billion | 1.7 billion | - |
| 2023-03-31 | 3.3 billion | 1.2 billion | 1.9 billion | - |
TAK Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 7.9 billion | 2.7 billion |
| 2023-09-30 | 7.0 billion | 2.3 billion |
| 2023-06-30 | 7.3 billion | 2.2 billion |
| 2023-03-31 | 7.2 billion | 2.3 billion |
TAK
Price: $13.37
Dividend Yield: 13.51%
Forward Dividend Yield: 4.50%
Payout Ratio: 162.46%
Dividend Per Share: 0.60 USD
Earnings Per Share: 0.37 USD
P/E Ratio: 37.30
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 2.3 million
Market Capitalization: 43.2 billion
Average Dividend Frequency: 3
Years Paying Dividends: 17
DGR3: -5.76%
DGR5: -4.78%
DGR10: -4.34%